Dabigatran Recalled Over Potential Carcinogen Dabigatran Recalled Over Potential Carcinogen

Ascend Labs issues voluntary nationwide recall of dabigatran etexilate capsules (75/150 mg) after detection of unacceptable levels of a nitrosamine impurity.News Alerts
Source: Medscape Internal Medicine Headlines - Category: Internal Medicine Tags: Cardiology News Alert Source Type: news